Major Role of Human Liver Microsomal Cytochrome P450 2C9 (CYP2C9) in the Oxidative Metabolism of Celecoxib, a Novel Cyclooxygenase-II Inhibitor

This publication has 21 references indexed in Scilit:

• Phenotypic and genotypic investigations of a healthy volunteer deficient in the conversion of losartan to its active metabolite E-3174
  Clinical Pharmacology & Therapeutics, 1999
• Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: Efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects
  Arthritis & Rheumatism, 1998
• Characterization of CYP2C19 and CYP2C9 from Human Liver: Respective Roles in Microsomal Tolbutamide,S-Mephenytoin, and Omeprazole Hydroxylations
  Archives of Biochemistry and Biophysics, 1998
• Synthesis and Biological Evaluation of the 1,5-Diarylpyrazole Class of Cyclooxygenase-2 Inhibitors: Identification of 4-[5-(4-Methylphenyl)-3- (trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, Celecoxib)
  Journal of Medicinal Chemistry, 1997
• Midazolam Hydroxylation by Human Liver Microsomes In Vitro: Inhibition by Fluoxetine, Norfluoxetine, and by Azole Antifungal Agents
  The Journal of Clinical Pharmacology, 1996
• Interaction of Sulfaphenazole Derivatives with Human Liver Cytochromes P450 2C: Molecular Origin of the Specific Inhibitory Effects of Sulfaphenazole on CYP 2C9 and Consequences for the Substrate Binding Site Topology of CYP 2C9
  Biochemistry, 1996
• Prostaglandin Endoperoxide H Synthases-1 and -2
  Published by Elsevier ,1996
• Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily
  Biochemical Pharmacology, 1994
• The demethylenation of methylenedioxymethamphetamine (“ecstasy”) by debrisoquine hydroxylase (CYP2D6)
  Biochemical Pharmacology, 1994
• Biochemical characterization of coumarin 7-hydroxylase activity in chick embryo liver microsomes
  Biochemical Pharmacology, 1992